Literature DB >> 27748044

Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients.

Cécile M Yelnik1, Monica Richey2, Virginia Haiduc2, Sotiria Everett3, Meng Zhang2, Doruk Erkan2.   

Abstract

OBJECTIVE: To determine if a cardiovascular disease (CVD) prevention counseling program for lupus patients decreases the prevalence of CVD risk factors.
METHODS: The assessment phase of a 3-year CVD prevention counseling program included the evaluation of CVD risk factors, diet, exercise habits, and medications. The education phase included discussion of the above risk factors, as well as CVD and thrombosis prevention strategies. Patients were prospectively followed every 3-6 months for risk assessment and continued education by a nurse practitioner and a medical doctor.
RESULTS: Between March 2009 and December 2014, 121 patients were included. At baseline, abnormal blood pressure, blood glucose, cholesterol profile, and body mass index were found in 50 (41%), 7 (6%), 82 (68%), and 77 (64%) patients, respectively. During the 3-year followup, among those with abnormal baseline values, prevalence of abnormal blood pressure significantly decreased (odds ratio [OR] 0.94, 95% confidence interval [95% CI] 0.92-0.96, P < 0.0001) with significant mean ± SD systolic blood pressure improvement (-6.12 ± 2.16 mm Hg; P < 0.05). The prevalence of abnormal cholesterol profile significantly decreased (OR 0.90, 95% CI 0.92-0.96) with significant improvements in mean ± SD high-density lipoprotein (+5.4 ± 0.36 mg/dl; P < 0.0001) and triglyceride levels (-12.6 ± 5.40 mg/dl; P < 0.05), and no significant change in blood glucose and body mass index was observed. At baseline, 100 (83%) and 95 (79%) patients had poor diet and physical activity, respectively; during the followup, both significantly improved in the entire population.
CONCLUSION: Our data suggest that a CVD prevention counseling program decreases the prevalence of some CVD risk factors in lupus patients.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 27748044      PMCID: PMC5733790          DOI: 10.1002/acr.23128

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  26 in total

1.  Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials.

Authors:  Luciana F Muniz; Rosa M R Pereira; Thiago F Silva; Eloisa Bonfá; Eduardo F Borba
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-09       Impact factor: 4.794

2.  Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids.

Authors:  R J Davies; M C E Lomer; S I Yeo; K Avloniti; S R Sangle; D P D'Cruz
Journal:  Lupus       Date:  2012-02-06       Impact factor: 2.911

3.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

4.  Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.

Authors:  S Demir; B Artim-Esen; Y Şahinkaya; Ö Pehlivan; N Alpay-Kanıtez; A Omma; B Erer; S Kamalı; A Gül; O Aral; L Öcal; M İnanç
Journal:  Lupus       Date:  2015-09-08       Impact factor: 2.911

5.  Diabetes and ischemic heart disease death in people age 25-54: a multiple-cause-of-death analysis based on over 400 000 deaths from 1990 to 2008 in New York City.

Authors:  Adriana Quinones; Iryna Lobach; Gil A Maduro; Nathaniel R Smilowitz; Harmony R Reynolds
Journal:  Clin Cardiol       Date:  2015-02       Impact factor: 2.882

6.  Cardiovascular risk assessment and treatment in systemic lupus erythematosus.

Authors:  Jennifer R Elliott; Susan Manzi
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-08       Impact factor: 4.098

7.  Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008.

Authors:  P Elfving; K Puolakka; H Kautiainen; L J Virta; T Pohjolainen; O Kaipiainen-Seppänen
Journal:  Lupus       Date:  2014-07-23       Impact factor: 2.911

8.  Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study.

Authors:  K Lerang; I-M Gilboe; D Steinar Thelle; J T Gran
Journal:  Lupus       Date:  2014-09-10       Impact factor: 2.911

9.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

10.  Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011.

Authors:  Louisa B Goss; Justin R Ortiz; Daryl M Okamura; Kristen Hayward; Christopher H Goss
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

View more
  3 in total

Review 1.  Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Authors:  Yu Zuo; Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2018-09-10       Impact factor: 4.592

Review 2.  Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences?

Authors:  Alessia Alunno; Francesco Carubbi; Elena Bartoloni; Davide Grassi; Claudio Ferri; Roberto Gerli
Journal:  Nutrients       Date:  2021-02-27       Impact factor: 5.717

3.  Genetic Background of Hypertension in Connective Tissue Diseases.

Authors:  Bogna Grygiel-Górniak; Iwona Ziółkowska-Suchanek; Elżbieta Kaczmarek; Mariusz Puszczewicz; Natalia Rozwadowska
Journal:  J Immunol Res       Date:  2020-02-03       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.